Sangamo +15% AH as first study of ZFN genome editing published in NEJM


Sangamo Biosciences (SGMO) +15.4% AH after announcing the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease-based genome editing technology in humans.

SGMO says data from the study, carried out in HIV-positive subjects, shows the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection, demonstrating the feasibility of this genome editing approach to achieve functional control of HIV.

From other sites
Comments (2)
  • RichMan02139
    , contributor
    Comment (1) | Send Message
     
    This is the real thing. I believe they will demonstrate increasing efficacy, dropping the viral levels to non detectable in more and more patients over time. There are a lot of bugs still to be worked out but appears that the treatment works.
    5 Mar 2014, 08:32 PM Reply Like
  • MineMan
    , contributor
    Comments (557) | Send Message
     
    And the results of the PH II Cytoxan Trials has not been presented yet.
    AMAZING AH trading.
    Press release at 12:15 ET 3/6/14
    Do not miss this one.
    6 Mar 2014, 12:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs